Oncbiomune building the board of directors.
https://www.sec.gov/Archives/edgar/data/13627...orm8-k.htm
Mr. Holcomb, age 48, has served as the president and owner of Holcomb CPA Firm, P.A. in Rolling Fork, MS since 2005. He also has been serving as the president and executive director of the MS Breast Foundation since July 2003. Mr. Holcomb earned his Bachelor of Business Administration degree from Delta State University in 1992. He is also Certified Public Accountant.
Grants of Options
On May 9, 2018, the Board approved the grant of stock options (the “Stock Options”) to purchase shares of the Company’s common stock to the directors and officer listed below. The Stock Options are exercisable at an exercise price of $ 0.0135 per share from May 9, 2018 to May 9, 2028.
Name Number of Options Granted
Andrew A. Kucharchuk 3,000,000
Jonathan F. Head 3,000,000
Daniel S. Hoverman 3,000,000
Charles L. Rice, Jr. 3,000,000
Robert Neal Holcomb 3,000,000
Not seeing Holcomb's form 4 yet.
This is building into something that could really make a mark. Not just in our accounts but also for prostate cancer.
https://www.sec.gov/Archives/edgar/data/13627...orm8-k.htm
Mr. Holcomb, age 48, has served as the president and owner of Holcomb CPA Firm, P.A. in Rolling Fork, MS since 2005. He also has been serving as the president and executive director of the MS Breast Foundation since July 2003. Mr. Holcomb earned his Bachelor of Business Administration degree from Delta State University in 1992. He is also Certified Public Accountant.
Grants of Options
On May 9, 2018, the Board approved the grant of stock options (the “Stock Options”) to purchase shares of the Company’s common stock to the directors and officer listed below. The Stock Options are exercisable at an exercise price of $ 0.0135 per share from May 9, 2018 to May 9, 2028.
Name Number of Options Granted
Andrew A. Kucharchuk 3,000,000
Jonathan F. Head 3,000,000
Daniel S. Hoverman 3,000,000
Charles L. Rice, Jr. 3,000,000
Robert Neal Holcomb 3,000,000
Not seeing Holcomb's form 4 yet.
This is building into something that could really make a mark. Not just in our accounts but also for prostate cancer.
